NeuroPace (NPCE) Set to Announce Quarterly Earnings on Wednesday

NeuroPace (NASDAQ:NPCE) will issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.10. The company had revenue of $18.01 million for the quarter, compared to the consensus estimate of $17.74 million. NeuroPace had a negative return on equity of 153.76% and a negative net margin of 50.38%. On average, analysts expect NeuroPace to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroPace Trading Down 1.9 %

NPCE opened at $13.64 on Monday. The stock’s fifty day moving average is $13.98 and its two-hundred day moving average is $11.92. The company has a market capitalization of $391.74 million, a P/E ratio of -10.66 and a beta of 2.06. NeuroPace has a 52 week low of $3.80 and a 52 week high of $18.15. The company has a quick ratio of 5.02, a current ratio of 5.71 and a debt-to-equity ratio of 2.76.

Insider Buying and Selling at NeuroPace

In other news, major shareholder Orbimed Advisors Llc sold 461,899 shares of NeuroPace stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $14.49, for a total transaction of $6,692,916.51. Following the completion of the sale, the insider now directly owns 3,542,068 shares in the company, valued at $51,324,565.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have sold 525,345 shares of company stock worth $7,583,250. 27.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on NPCE. Leerink Partnrs reissued an “outperform” rating on shares of NeuroPace in a research report on Tuesday, January 30th. SVB Leerink began coverage on NeuroPace in a research report on Tuesday, January 30th. They issued an “outperform” rating and a $22.00 price target for the company. Wells Fargo & Company raised NeuroPace from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $16.00 to $20.00 in a research report on Thursday, March 14th. Morgan Stanley boosted their price target on NeuroPace from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 6th. Finally, Cantor Fitzgerald boosted their price target on NeuroPace from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.67.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.